Trump Suggests Reevaluation of Kratom Derivative 7-OH Amid FDA Concerns
In a notable shift, President Trump has indicated that certain forms of the kratom derivative 7-OH may warrant approval, despite prior warnings from the FDA about its risks.
Editorial Staff
1 min read
Updated 9 days ago
On May 11, 2026, President Trump expressed a willingness to consider regulatory approval for specific forms of 7-OH, a derivative of kratom that has recently attracted attention for its effects.
This statement comes in the wake of the FDA's warnings issued last year regarding the potential dangers of natural opioids derived from kratom, which have been linked to harmful products.
Trump's remarks suggest a possible change in the administration's approach to the regulation of substances related to kratom, raising questions about the future of 7-OH in the market.